Oncology – Page 11

Enhanced Pathologic Response in Head and Neck Squamous Cell Carcinoma with Neoadjuvant Chemoimmunotherapy

By MedXY 08/25/2026

Neoadjuvant chemoimmunotherapy significantly improves pathologic response rates in resectable head and neck squamous cell carcinoma compared to immunotherapy alone, potentially transforming preoperative treatment strategies.

$Enhanced Salvage Therapy in Relapsed/Refractory AML: Venetoclax Plus High-Dose Cytarabine and Mitoxantrone Shows Promising Outcomes and Risk Stratification Insights$

Hematology-Oncology news Oncology

Enhanced Salvage Therapy in Relapsed/Refractory AML: Venetoclax Plus High-Dose Cytarabine and Mitoxantrone Shows Promising Outcomes and Risk Stratification Insights

By MedXY 08/24/2026

A multicenter real-world study demonstrates that combining venetoclax with high-dose cytarabine and mitoxantrone significantly improves remission and survival rates in relapsed/refractory AML, with validated risk factors guiding prognostication.

Hematology-Oncology news Oncology

Oncogenic DHX15 Mutation Drives Mitochondrial Metabolism to Sustain Leukemia Stemness in AML

By MedXY 08/24/2026

A hotspot DHX15R222G mutation collaborates with AML1-ETO fusion to enhance mitochondrial function and leukemia stem cell activity, leading to poorer prognosis and chemotherapy resistance in AML, unveiling OXPHOS inhibition as a promising targeted therapy.

news Oncology Otorhinolaryngology

Enhanced Pathologic Responses with Neoadjuvant Chemoimmunotherapy in Resectable Head and Neck Squamous Cell Carcinoma

By MedXY 08/24/2026

Neoadjuvant chemoimmunotherapy significantly improves pathologic complete and major responses compared to immunotherapy alone in resectable head and neck squamous cell carcinoma, suggesting a promising avenue to improve treatment outcomes.

Clinical Updates news Oncology Otorhinolaryngology

Impact of Neighborhood Socioeconomic Deprivation on Breslow Thickness and Clinical Outcomes in Head and Neck Cutaneous Melanoma: A Comprehensive Review

By MedXY 08/24/2026

This review synthesizes evidence linking neighborhood socioeconomic deprivation with increased Breslow thickness and delayed surgical management in head and neck cutaneous melanoma, highlighting potential mechanisms and clinical implications.

news Oncology Otorhinolaryngology

TERT Promoter Variants and Age: Refining Prognostic Precision in Papillary Thyroid Carcinoma

By MedXY 08/23/2026

This analysis reveals that TERT promoter mutations, increasingly prevalent with age, better predict poor outcomes in papillary thyroid carcinoma than age alone, offering enhanced risk stratification for clinical management.

General Surgery news Oncology

Beyond Survival: Longitudinal Health-related Quality of Life After Hepatectomy for High-risk Colorectal Liver Metastases

By MedXY 08/22/2026

This prospective study reveals that health-related quality of life (HR-QoL) declines immediately after hepatectomy for high-risk colorectal liver metastases but returns to or surpasses baseline by one year in patients without recurrence, underscoring the impact of cancer recurrence on long-term quality of life.

news OB/GYN & Women's Health Oncology

Trends in Incidence, Mortality, and Survival of Endometrial, Ovarian, and Cervical Cancers in Young Nordic Women: Insights from 40 Years of Registry Data

By MedXY 08/22/2026

This article analyzes 40-year trends in incidence, mortality, and survival of endometrial, ovarian, and cervical cancers among Nordic women aged 0-49, highlighting evolving epidemiology and implications for age-specific prevention.

Clinical Updates news OB/GYN & Women's Health Oncology

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups

By MedXY 08/22/2026

This review contrasts early- and late-phase gynecologic oncology trials, underscoring disparities in trial completion, publication, and racial/ethnic minority enrollment, highlighting the need to improve inclusivity and reporting.

Gastroenterology news Oncology

Gut Microbiota and Metabolomic Signatures as Predictors of Immunotherapy Outcomes in MASLD and Viral HCC

By MedXY 08/22/2026

Distinct gut microbial profiles but shared metabolomic markers, especially fecal acetate, predict response and survival with combination immunotherapy in metabolic dysfunction-associated and viral hepatitis-related hepatocellular carcinoma.

Gastroenterology news Oncology

Metabolic Checkpoint Role of PCK1 Deficiency in Promoting MASH-HCC via 12-HETE-Induced CD8+ T Cell Dysfunction

By MedXY 08/22/2026

PCK1 deficiency in hepatocytes drives metabolic reprogramming that fosters MASH-HCC progression by inducing CD8+ T cell dysfunction through 12-HETE-p38 signaling, highlighting a metabolic immunotherapy target to enhance anti-PD-1 efficacy.

news Oncology

Divergent Roles of Federal and Industry Sponsors in US Cancer Clinical Trials: Insights from 2008 to 2024

By MedXY 08/22/2026

This study quantifies how federal and industry sponsorship differ in US cancer clinical trials, highlighting complementary focuses: industry emphasizes single-agent drug therapies, while federal trials prioritize multimodality regimens, rare cancers, pediatric populations, and supportive care.

news Oncology Otorhinolaryngology

Pembrolizumab Plus Quad-Shot Radiotherapy: A Promising Approach for Recurrent, Unresectable Head and Neck Cancer

By MedXY 08/21/2026

A phase 2 trial shows pembrolizumab combined with low-dose quad-shot radiotherapy yields encouraging response rates and survival outcomes in recurrent, unresectable head and neck squamous cell carcinoma.

General Surgery news Oncology

Evaluating Preoperative High-Dose Corticosteroids in Digestive Cancer Surgery: Insights from a Large Multicenter Randomized Trial

By MedXY 08/21/2026

A large randomized clinical trial demonstrated that preoperative high-dose corticosteroids do not reduce major postoperative complications in elective digestive cancer surgery, challenging their routine use for perioperative inflammation control.

news Oncology Pathology & Lab Medicine/Bệnh học

New 2026 Multisociety Guidelines for Atypical Breast Lesions and LCIS: What Clinicians Need to Know

By MedXY 08/21/2026

Multisociety 2026 guidance clarifies diagnosis and management of atypical breast lesions and lobular carcinoma in situ, balancing excision, surveillance, and chemoprevention based on lesion type, radiologic concordance, and risk.

General Surgery news Oncology

Navigating Intraoperative Challenges in Robot-assisted Minimally Invasive Esophagectomy: Incidence, Management, and Surgical Outcomes

By MedXY 08/21/2026

This article examines the incidence and management of intraoperative adverse events during robot-assisted minimally invasive esophagectomy, highlighting their impact on surgical results and postoperative recovery.

Gastroenterology news Oncology

Patterns and Implications of Local Regrowth After Neoadjuvant Chemoradiotherapy in Esophageal Cancer: Insights from the SANO Trial

By MedXY 08/21/2026

This study analyzes surgical specimens from the SANO trial, revealing that local regrowth after neoadjuvant chemoradiotherapy predominantly involves mucosa and submucosa and supports endoscopic monitoring in active surveillance, with surgery advised due to nodal disease risk.

news OB/GYN & Women’s Health Oncology

Enhancing Patient Engagement in Gynecologic Oncology Clinical Trials Through a Pilot Patient Ambassador Program

By MedXY 08/21/2026

A pilot program using former gynecologic oncology trial participants as patient ambassadors improved confidence and perceptions about clinical trials among trial-naïve patients, highlighting a feasible peer-education approach.

news OB/GYN & Women’s Health Oncology

Niraparib Versus Platinum-Taxane Chemotherapy as Neoadjuvant Treatment in Advanced HR-Deficient Ovarian Cancer: Insights from the OPAL Phase 2 Trial

By MedXY 08/21/2026

The OPAL phase 2 trial compared neoadjuvant niraparib to standard platinum-taxane chemotherapy in newly diagnosed HR-deficient advanced ovarian cancer, showing inferior response rates with niraparib and a safety profile consistent with PARP inhibitors.

news OB/GYN & Women’s Health Oncology

Disparities in Gynecologic Cancer Diagnosis in the U.S. (2001–2019): The Roles of Race, Social Vulnerability, and Specialist Access

By MedXY 08/21/2026

This analysis of nearly 1.4 million U.S. gynecologic cancer cases reveals that racial/ethnic minorities, socially vulnerable communities, and women lacking geographic access to gynecologic oncologists face higher odds of late-stage cancer diagnosis, with implications for targeted interventions.